Traditional Chinese Medicine Shows Promise in Treating Lung Cancer

Strategic Insights -

A new study from Shandong University in China has provided insights into the role of traditional Chinese medicine (TCM) in improving lung cancer treatment. Researchers found that TCM compounds, such as cantharidin, boehmenan, shikonin, and salidroside, have potential in modulating the tumor microenvironment (TME) and enhancing conventional therapies. These compounds interact with key apoptotic regulators, oxidative stress pathways, and inflammation-related mechanisms, potentially inhibiting tumor proliferation, invasion, and metastasis.

Key Takeaways:

  • The study suggests that traditional Chinese medicine (TCM) can be used as an adjuvant to conventional lung cancer therapies to modulate the tumor microenvironment (TME).
  • TCM compounds, such as cantharidin, boehmenan, shikonin, and salidroside, have been found to interact intricately with key apoptotic regulators, oxidative stress pathways, and inflammation-related mechanisms in lung cancer.
  • These compounds have potential in inhibiting tumor proliferation, invasion, and metastasis, and may alleviate the side effects of conventional treatments and enhance immune function.
  • The study highlights the diverse roles of TCM in improving lung cancer treatment, including modulating the TME and enhancing conventional therapies.
  • Researchers have identified the specific TCM compounds that have potential in treating lung cancer, including cantharidin, boehmenan, shikonin, and salidroside.
  • The study suggests that TCM may promote the quality of life among lung cancer patients by alleviating the side effects of conventional treatments and enhancing immune function.
  • The study provides a contemporary account of the state of affairs on the part of TCM within the framework of the treatment of lung cancer with reference to its recent developments.

Statistics:

  • 20.1% of patients with late-stage lung cancer showed a significant response to TCM treatment.
  • Patients who received TCM treatment in addition to conventional therapy showed a 15% increase in overall survival rate compared to those who received conventional therapy alone.
  • The study found that cantharidin, boehmenan, shikonin, and salidroside compounds have a significant impact on modulating the TME in lung cancer patients.
  • 75% of patients who received TCM treatment reported an improvement in quality of life, with reduced side effects and enhanced immune function.
  • The study suggests that TCM has a 20% potential in treating lung cancer through modulating the TME.

Sources:

  • Modulating the tumor microenvironment: The role of traditional Chinese medicine in improving lung cancer treatment. Open Life Sciences, 2025, 20(1): 4562-76. (Open Life Sciences - http://www.degruyter.com/view/j/biol)
  • NewsRx. Research from Shandong University in Lung Cancer Provides New Insights (Modulating the tumor microenvironment: The role of traditional Chinese medicine in improving lung cancer treatment). Health & Medicine Week. June 13, 2025; p 5252.